Drug intelligence / Profile preview

WRR-112

Development stage: Unknown
Modality: Peptides, Small Molecules

Overview

WRR-112 is an experimental peptide-like chemical compound that functions as a cysteine protease inhibitor. It is an analog of E-64 and has been shown to inhibit Cruzipain and Cathepsin F.

Other names: N-[3-CARBOXY-2-HYDROXY-PROPIONYL]-L-HOMOPHENYLALANYL-AMINO-2-METHYLBUTANEAC1NRD12AC-1NRD12AC 1NRD12DB03691DB-03691DB 03691

Targets

CTSF (Cathepsin F)Cruzipain

Beyond the preview

Go deeper on WRR-112.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WRR-112.

Explore the full profile